Novel therapeutic options for Waldenstrms macroglobulinemia
The therapeutic potential for Waldenstrms macroglobulinemia (WM) is widening, with our growing understanding and knowledge of the genetics behind this disease. In this interview at the 1st European ... Author: VJHemOnc Added: 07/20/2018
CONCLUSIONS: JL1 positivity was associated with superior complete response and less BM involvement in NHL following chemotherapy. PMID: 31432632 [PubMed - in process]
Condition: Waldenstrom Macroglobulinemia Interventions: Drug: Ibrutinib; Drug: Rituximab Sponsor: Janssen Pharmaceutical K.K. Not yet recruiting
X-linked agammaglobulinemia (XLA), caused by a mutation in the Bruton’s tyrosine kinase (BTK) gene, is rarely reported in patients with recurrent hemophagocytic lymphohistiocytosis (HLH). This mutation leads to significantly reduced numbers of circulatory B cells and serum immunoglobulins in patients. Therefore, they exhibit repetitive bacterial infections since infancy, and immunoglobulin (Ig) replacement therapy is the primary treatment. HLH is a life-threatening condition with manifestations of nonremitting fever, hepatosplenomegaly, cytopenias, coagulopathy, lipid disorder, and multiple organ failure. It is cause...
Condition: Waldenstrom Macroglobulinemia Interventions: Drug: Dexamethasone, cyclophosphamide, rituximab; Drug: Rituximab, ibrutinib Sponsors: University College, London; Janssen-Cilag Ltd. Not yet recruiting
Conditions: Mantle Cell Lymphoma; Waldenström Macroglobulinemia Intervention: Drug: Zanubrutinib Sponsor: BeiGene Available